Glaucoma

Proprietary Factor 5A1 shows promise for controlling glaucoma

Published in Cancer Weekly, January 6th, 2004

Senesco Technologies, Inc., (SNT) has demonstrated that inhibition of its proprietary gene, Eukaryotic Translation Initiation Factor 5A1 (Factor 5A1), can significantly reduce apoptosis (cell death) caused by tumor necrosis factor alpha (TNF-alpha).

TNF-alpha is a powerful pro-inflammatory cytokine that mediates the response of the immune system to infection and trauma, and it is known to activate apoptosis as well as cause inflammation.

Senesco performed tests on lamina cribrosa cells from the human optic nerve head and on an epithelial cell line from the human intestine using a newly synthesized highly specific inhibitor of Factor 5A1...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-01-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry